Clinical studies and scientific literatures

Articles on Tella’s dendritic cell vaccine therapy are published in European and United States academic journals

Published date Name of the journal Author Title
July 23, 2014 『Clinical Cancer Research』 Shigeo Koido et al.
The Jikei University School of Medicine
Evaluation of safety and efficacy of Vaccell with Wilms’ Tumor 1 (WT1) Class I/II peptides for patients with advanced pancreatic cancer
May 7, 2014 『Journal of Ovarian Research』 Masanori Kobayashi et al.
Hospital Director,
Seren Clinic Nagoya
The feasibility and clinical effects of dendritic cell cancer vaccine therapy for patients with recurrent ovarian cancer
April 29, 2014 『Cancer Immunology, Immunotherapy』 Masanori Kobayashi, Hospital Director,
et al
Seren Clinic Nagoya
Additional effects of dendritic cell vaccine therapy combined with chemotherapy for survival prolongation of patients with unresectable pancreatic cancer: Multi-centered study
July 20, 2013 『Journal of Gastrointestinal Surgery』 Masanori Kobayashi et al.
Hospital Director,
Seren Clinic Nagoya
A study on the benefits and prognostic factors for a dendritic cell vaccine therapy in patients with unresectable advanced/recurrent biliary tract cancer
December 11, 2012 『European Journal of Cancer』 “European Journal of Cancer”
Hidenori Takahashi et al.
Hospital Director,Seren Clinic Tokyo
A study on the benefits and prognostic factors for a dendritic cell vaccine therapy employing WT1 in patients with advanced non-small cell lung cancer
July 22, 2011 『Pancreas』 Yukino Kimura et al.
Department of Research and Development,
Tella Inc.
Clinical experiences and immunological analytic results of the dendritic cell vaccine therapy combined with an anticancer drug in patients with advanced pancreatic cancer

TopPage